Related Experiment Video
Updated: Oct 22, 2025
06:04
Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
Published on: August 8, 2025
262
Rivaroxaban Experience at Tertiary Care Centre in Saudi Arabia:A Retrospective Observational Study
Muhammad Riazuddin1, Mohamed Ahmed Mpharm1, Muhammad Imran Butt1
1King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
Galen Medical Journal
|September 1, 2021
Summary
Rivaroxaban use in Saudi Arabia showed effectiveness and safety for atrial fibrillation and venous thromboembolism. Bleeding and thrombosis rates were comparable to major clinical trials, supporting its use in real-world practice.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Practice
Background:
- Atrial fibrillation (AF) and Venous Thromboembolism (VTE) are major causes of morbidity and mortality.
- Direct oral anticoagulants (DOACs) offer an alternative to Vitamin K Antagonists (VKAs) with potentially less bleeding.
- Assessing DOACs in real-world settings is crucial for understanding their clinical utility.
Purpose of the Study:
- To evaluate the safety and effectiveness of rivaroxaban in a large Saudi Arabian tertiary referral center.
- To compare real-world outcomes with data from major clinical trials.
- To assess rivaroxaban's performance across a diverse patient population.
Main Methods:
- Retrospective analysis of 509 patients prescribed rivaroxaban.
- Inclusion of patients treated for non-valvular AF and VTE.
- Systematic recording of adverse events, including major bleeding, thrombosis, and mortality.
Main Results:
- Rivaroxaban was prescribed for non-valvular AF (65.3%) and VTE (34.7%).
- Overall bleeding occurred in 14.1% of patients (3.9% major bleeds).
- Thrombosis events occurred in 2.5% of patients, with a 2.7% all-cause mortality rate.
Conclusions:
- Rivaroxaban demonstrated comparable safety and effectiveness in clinical practice to major trials.
- The study provides valuable insights into DOAC utilization in the Middle East.
- Real-world data supports rivaroxaban's role in managing AF and VTE.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
64
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
64
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
75
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
75
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
74
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
74
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.5K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.5K
01:19Pharmacovigilance
1.2K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.2K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.1K